Chengyi Pharmaceutical: The active pharmaceutical ingredient dobudamine hydrochloride has received market approval.

Sincerity Pharmaceutical Announcement: The company has recently received the "Chemical Raw Material Drug Market Application Approval Notice" issued by the National Medical Products Administration for the raw material drug Dopamine Hydrochloride. This raw material drug is used for the treatment of cardiovascular diseases, belongs to beta receptor agonists, stimulates the heart's beta 1 receptors to enhance myocardial contractility, while also dilating peripheral blood vessels and reducing cardiac load. Currently, domestic manufacturers include Zhejiang Ruixin Pharmaceutical and Shanghai Ziyuan Pharmaceutical. The company has not been able to obtain information on the sales of this product from public channels. The company has accumulated research and development investment in this raw material drug project of approximately 5.1982 million RMB. Obtaining market approval this time will enrich the company's product line and help expand business areas, but it will not have a significant impact on current performance.